Komori
General Meetings of Shareholders4570Immuno-Biological Laboratories Co.,Ltd.Pharmaceuticals

Notice of Convocation of the 44th Annual General Meeting of Shareholders and General Meeting Materials

At the 44th Annual General Meeting of Shareholders, the Company will submit proposals concerning the appropriation of surplus, amendments to the Articles of Incorporation, the election of directors and directors who are Audit and Supervisory Committee Members, and the setting of directors’ remuneration. The amendments to the Articles of Incorporation will transition the Company from a company with an Audit and Supervisory Board to a company with an Audit and Supervisory Committee.

Worth reading
67In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Conditional
How definitive the wording is.

Resolutions for the General Meeting of Shareholders

Annual (44th fiscal period)
2026
Jun 25
Date and time22 days from this disclosure to the meeting
Matters for resolution6 items
  1. Appropriation of surplus

  2. Partial Amendments to the Articles of Incorporation

  3. Election of 4 Directors (excluding Directors serving as Audit and Supervisory Committee Members)

  4. Election of 3 directors serving as Audit and Supervisory Committee members

  5. Setting the remuneration for directors (excluding directors serving as Audit and Supervisory Committee members)

  6. Setting the remuneration for directors serving as Audit and Supervisory Committee members

Shareholder Proposal

No

A shareholder proposal is a resolution submitted by a shareholder, rather than by the company.
Director nominee7 candidates: 3 new candidates and 7 outside directors (candidates for Audit and Supervisory Committee Members).
Resolutions for the General Meeting of Shareholders
ItemDetails
Type of shareholders' meetingAnnual (44th fiscal period)
Date and time11:00 a.m. on Thursday, 25 June 2026
Matters for resolutionProposal 1: Appropriation of surplus, Proposal No. 2: Partial Amendments to the Articles of Incorporation, Proposal No. 3: Election of 4 Directors (excluding Directors serving as Audit and Supervisory Committee Members), Proposal No. 4: Election of 3 directors serving as Audit and Supervisory Committee members, Proposal 5: Setting the remuneration for directors (excluding directors serving as Audit and Supervisory Committee members), Proposal 6: Setting the remuneration for directors serving as Audit and Supervisory Committee members
Shareholder ProposalNo
Director nominee7 candidates: 3 new candidates and 7 outside directors (candidates for Audit and Supervisory Committee Members).
Items this document does not state (1)
Percentage voting in favor

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To strengthen the Board of Directors’ oversight function and corporate governance, and to accelerate management decision-making and execution.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice of Convocation of the 44th Annual General Meeting of Shareholders and General Meeting Materials | Immuno-Biological Laboratories Co.,Ltd. (4570) timely disclosure | Komori